SciELO - Scientific Electronic Library Online

 
vol.29 número3Modulación de la fisiología gastrointestinal mediante cepas probióticas de Lactobacillus casei y Bifidobacterium bifidumConocimientos, comportamientos y opiniones de los profesionales sanitarios de un hospital en relación a la confidencialidad índice de autoresíndice de assuntospesquisa de artigos
Home Pagelista alfabética de periódicos  

Serviços Personalizados

Journal

Artigo

Indicadores

Links relacionados

  • Em processo de indexaçãoCitado por Google
  • Não possue artigos similaresSimilares em SciELO
  • Em processo de indexaçãoSimilares em Google

Compartilhar


Anales del Sistema Sanitario de Navarra

versão impressa ISSN 1137-6627

Resumo

CORDOBA, A. et al. Modulation of biomarkers expression (OR, PR and C-erbB2) in breast cancer following neoadjuvant treatment. Anales Sis San Navarra [online]. 2006, vol.29, n.3, pp.349-356. ISSN 1137-6627.

Introducción: Pre and post-operative oncological therapy in patients with breast cancer is determined, amongst other factors, by hormone receptor status and by c-erbB2 expression. The aim of this study is to determine the influence of neoadjuvant therapy on the expression of oestrogen receptor (OR), progesterone receptor (PR) and c-erbB2. Methods. Fifty-three patients with breast cancer diagnosed by tru-cut biopsy were studied. Patients with locally advanced carcinoma (20) had preoperative treatment. All patients underwent surgical resection. Expression of OR, PR and c-erbB2 in both the tru-cut biopsy and the gross specimen was compared. Results: We found significant differences in OR, PR expression in both biopsy and gross specimen, between the group of patients who underwent neoadjuvant treatment and the group without pre-surgical treatment. Changes in PR, OR and c-erbB2 status were found between the tru-cut biopsy and the gross specimen, in about 10 to 40% of the cases who received neoadjuvant therapy. These changes had no statistical significance.

Palavras-chave : Oestrogen receptors; Progesterone receptors; C-erbB2; Neoadjuvant therapy.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )

 

Creative Commons License Todo o conteúdo deste periódico, exceto onde está identificado, está licenciado sob uma Licença Creative Commons